AbbVie Receives FDA Approval for Rinvoq in Giant Cell Arteritis

AbbVie today announced that the FDA has approved Rinvoq (upadacitinib) for the treatment of adults with giant cell arteritis (GCA). GCA is a systemic vasculitis affecting large and medium-sized blood vessels, primarily in patients over 50 years of age. In the Phase 3 SELECT-GCA trial, Rinvoq demonstrated a statistically significant improvement in the proportion of patients achieving sustained remission compared to placebo. Upadacitinib is an oral JAK inhibitor that selectively inhibits JAK1. This approval expands Rinvoq's use into GCA, adding to its existing approvals in rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and other inflammatory conditions.